Alternative methods for the treatment of vasomotor symptoms in postmenopausal women


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Objective. To analyze data on the efficiency and safety of alternative treatments for vasomotor symptoms in postmenopausal women, by leaning on recent documentary data. Material and methods. The review presents the data of randomized controlled studies, systematic reviews, and meta-analyses in the past five years, as well as the consensus opinion of the experts of international menopause societies, which is given in the 2015-2016 guidance documents. Results. There is evidence on the efficiency and safety of lifestyle modification, dietary supplements, alternative non-drug treatments, herbal remedies, and neuroactive agents for the treatment of postmenopausal vasomotor symptoms. There are also results of two large surveys reflecting the extent of use of these treatment options, their advantages and disadvantages in the view of women themselves. Conclusion. A clinician must be aware of the level of evidence regarding the efficiency and safety of alternative means in order preclude the insufficient use of effective treatment options for postmenopausal vasomotor symptoms, and conversely, the use of treatments that are ineffective or inappropriate in specific clinical situations.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Svetlana Yureneva

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
Ph.D., leading researcher, gynecological endocrinology department

Lilia Ilyina

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: bseiljina@mail.ru
PhD, secretary of the Association of Endocrinologists Gynecologists

Zuhra Ebzieva

Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: zu87@list.ru
post-graduate, department of gynecological endocrinology

Әдебиет тізімі

  1. Freeman E.W., Sammel M.D., Sanders R.J. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014; 21(4): 339-46.
  2. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al.; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015; 175(4): 531-9.
  3. Gartoulla P., Worsley R., Bell R.J., Davis S.R. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause. 2015; 22(7): 687-8.
  4. Zeleke B.M., Bell R.J., Billah B., Davis S.R. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil. Steril. 2016; 105(1): 149-55.
  5. National Institute for Health and Clinical Excellence. NICE Clinical Guideline Menopause. 2015. Available at: https://www.nice.org.uk/guidance/ng23/ resources/menopause-diagnosis-and-management-1837330217413
  6. Stuenkel C.A., Davis S.R., Gompel A., Lumsden M.A., Murad M.H., Pinkerton J.V., Santen R.J. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2015; 100(11): 3975-4011.
  7. Сметник В.П., ред. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации (протокол лечения). М.; 2015. [Smetnik V.P., ed. Menopausal hormone therapy and maintaining the health of middle-aged women. Clinical guidelines (treatment protocol). Moscow; 2015. (in Russian)]
  8. Baber R.J., Panay N., Fenton A., the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
  9. Maclennan A.H., Broadbent J.L., Lester S., Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst. Rev. 2004; (4): CD002978.
  10. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288(3): 321-33.
  11. Studd J. «PROFOX» - the post HRT nightmare. Climacteric. 2011; 14(2): 217-9.
  12. Mintziori G., Lambrinoudaki I., Goulis D.G., Ceausu I., Depypere H., Erel C.T. et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms. Maturitas. 2015; 81(3): 410-3.
  13. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155-74.
  14. Daley A., Stokes-Lampard H., Thomas A., MacArthur C. Exercise for vasomotor menopausal symptoms. Cochrane Database Syst. Rev. 2014; (11): CD006108.
  15. Lethaby A., Marjoribanks J., Kronenberg F., Roberts H., Eden J., Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst. Rev. 2013; (12): CD001395.
  16. Taku K., Melby M.K., Kronenberg F., Kurzer M.S., Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012; 19(7): 776-90.
  17. Li L., Lv Y., Xu L., Zheng Q. Quantitative efficacy of soy isoflavones on menopausal hot flashes. Br. J. Clin. Pharmacol. 2015; 79(4): 593-604.
  18. Schmidt M., Arjomand-Wölkart K., Birkhäuser M.H., Genazzani A.R., Gruber D.M., Huber J. et al. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. Gynecol. Endocrinol. 2016; 32(6): 427-30. doi: 10.3109/09513590.2016.1152240.
  19. EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS). Risk assessment for peri- and postmenopausal women taking food supplements containing isolated isoflavones. EFSA J. 2015; 13(10): 4246.
  20. Setchell K.D., Clerici C. Equol: history, chemistry, and formation. J. Nutr. 2010; 140(7): 1355S-62S.
  21. Lipovac M., Chedraui P., Gruenhut C., Gocan A., Kurz C., Neuber B., Imhof M. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol. Endocrinol. 2012; 28(3): 203-7.
  22. Edena J.A. Phytoestrogens for menopausal symptoms: a review. Maturitas. 2012; 72(2): 157-9.
  23. Leach M.J., Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst. Rev. 2012; (9): CD007244.
  24. Medicines and Healthcare products Regulatory Agency (MHRA). Liver failure case highlights need to use Black Cohosh remedies carefully. MHRA Press; 2012. Available at: press.office@mhra.psi.gov.uk
  25. Fritz H., Seely D., McGowan J., Skidmore B., Fernandes R., Kennedy D.A. et al. Black cohosh and breast cancer: a systematic review. Integr. Cancer Ther. 2014; 13(1): 12-29.
  26. Chiu H.Y., Pan C.H., Shyu Y.K., Han B.C., Tsai P.S. Effects of acupuncture on menopause-related symptoms and quality of life in women in natural menopause: a meta-analysis of randomized controlled trials. Menopause. 2015; 22(2): 234-44.
  27. Dodin S., Blanchet C., Marc I., Ernst E., Wu T., Vaillancourt C. et al. Acupuncture for menopausal hot flushes. Cochrane Database Syst. Rev. 2013; (7): CD007410.
  28. Norton S., Chilcot J., Hunter M.S. Cognitive-behavior therapy for menopausal symptoms (hot flashes and night sweats): moderators and mediators of treatment effects. Menopause. 2014; 21(6): 574-8.
  29. Saensak S., Vutyavanich T., Somboonporn W., Srisurapanont M. Relaxation for perimenopausal and postmenopausal symptoms. Cochrane Database Syst. Rev. 2014; (7): CD008582.
  30. Green S.M., Key B.L., McCabe R.E. Cognitive-behavioral, behavioral, and mindfulness-based therapies for menopausal depression: a review. Maturitas. 2015; 80(1): 37-47.
  31. Nelson H.D., Vesco K.K., Haney E., Fu R., Nedrow A., Miller J. et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006; 295(17): 2057-71.
  32. Shams T., Firwana B., Habib F., Alshahrani A., Alnouh B., Murad M.H., Ferwana M. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J. Gen. Intern. Med. 2014; 29(1): 204-13.
  33. Sun Z., Hao Y., Zhang M. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials. Gynecol. Obstet. Invest. 2013; 75(4): 255-62.
  34. Rada G., Capurro D., Pantoja T., Corbalán J., Moreno G., Letelier L.M., Vera C. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Syst. Rev. 2010; (9): CD004923.
  35. Fisher W.I., Johnson A.K., Elkins G.R., Otte J.L., Burns D.S., Yu M., Carpenter J.S. Risk factors, pathophysiology, and treatment of hot flashes in cancer. CA Cancer J. Clin. 2013; 63(3): 167-92.
  36. Simon J.A., Portman D.J., Kaunitz A.M., Mekonnen H., Kazempour K., Bhaskar S., Lippman J. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause. 2013; 20(10): 1027-35.
  37. Joffe H., Guthrie K.A., LaCroix A.Z., Reed S.D., Ensrud K.E., Manson J.E. et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venla-faxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern. Med. 2014; 174(7): 1058-66.
  38. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 2003; 95(23): 1758-64.
  39. Haney E.M., Warden S.J., Bliziotes M.M. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? Bone. 2010; 46(1): 13-7.
  40. Hayes L.P., Carroll D.G., Kelley K.W. Use of gabapentin for the management of natural or surgical menopausal hot flashes. Ann. Pharmacother. 2011; 45(3): 388-94.
  41. Toulis K.A., Tzellos T., Kouvelas D., Goulis D.G. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin. Ther. 2009; 31(2): 221-35.
  42. Aguirre W., Chedraui P., Mendoza J., Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol. Endocrinol. 2010; 26(5): 333-7.
  43. Boekhout A.H., Vincent A.D., Dalesio O.B., van den Bosch J., Foekema-Töns J.H., Adriaansz S. et al. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 2011; 29(29): 3862-8.
  44. Peng W., Adams J., Sibbritt D.W., Frawley J.E. Critical review of complementary and alternative medicine use in menopause: focus on prevalence, motivation, decision-making, and communication. Menopause. 2014; 21(5): 536-48.
  45. Gentry-Maharaj A., Karpinskyj C., Glazer C., Burnell M., Ryan A., Fraser L. et al. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study. Menopause. 2015; 22(4): 384-90.
  46. Schierbeck L.L., Rejnmark L., Tofteng C.L., Stilgren L., Eiken P., Mosekilde L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ. 2012; 345: e6409.
  47. Lobo R.A. The hope for KEEPS. Climacteric. 2015; 18(2): 108-9.
  48. Hodis H.N., Mack W.J., Henderson V.W., Shoupe D., Budoff M.J., Hwang-Levine L. et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 2016; 374(13): 1221-31.
  49. Rossouw J.E., Manson J.E., Kaunitz A.M., Anderson G.L. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet. Gynecol. 2013; 121(1): 172-6.
  50. Boardman H.M., Hartley L., Eisinga A., Main C., Roqué i Figuls M., Bonfill Cosp X. et al. Hormone therapy for preventing cardiovascular disease in postmenopausal women. Cochrane Database Syst. Rev. 2015; (3): CD002229.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>